EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of 124 I-MIBG Dosimetry-Guided High-Activity 131 I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma

Ines Maric, Manuel Weber, Andre Prochnow, Jochen Schmitz, Nicole Unger, Benedikt M Schaarschmidt, Thorsten D Poeppel, Christoph Rischpler, Andreas Bockisch, Ken Herrmann, Walter Jentzen, Wolfgang P Fendler

Journal of Nuclear Medicine · 2023-06 · 64 (6) · 885-891

DOI: 10.2967/jnumed.122.264775 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 02.02.2023. Verfasst von Ines Maric und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany; ines.maric@uk-essen.de. Hauptthemen laut MEDLINE: Pheochromocytoma, Neuroblastoma, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aim to evaluate the efficacy and safety of 124I-metaiodobenzylguanidine (MIBG) dosimetry-guided high-activity 131I-MIBG therapy of advanced pheochromocytoma or neuroblastoma.

Methods

Fourteen patients with advanced pheochromocytoma or neuroblastoma, age 9-69 y, underwent 124I-MIBG PET scans and whole-body retention measurements to assess the whole-body dose as a surrogate of bone marrow toxicity and tumor (absorbed) dose per unit of administered activity. Dosimetry results together with individual patient characteristics were combined to guide a single therapeutic activity to achieve a high tumor dose without exceeding toxicity threshold. Toxicity was assessed for hematologic, hepatic, and renal function. Response was evaluated by RECIST, International Society of Pediatric Oncology Europe Neuroblastoma-like score, change in PET uptake, and quantitative PET parameters (SUVmax, SUVpeak, metabolic tumor volume, total lesion glycolysis), as well as visual decrease in number or in visual intensity of lesions on baseline to follow-up 124I-MIBG PET/CT.

Results

The average therapeutic activity was 14 GBq. Eleven of 14 patients (79%) received each more than 10 GBq. One male patient was treated with a single activity of 50 GBq. Three patients were treated with lower activities between 3.5 and 7.0 GBq. Median overall survival was 85 mo (95% CI), and median progression-free survival was 25 mo (95% CI). Four (29%) and 5 (36%) patients demonstrated response (complete response or partial response) by RECIST and functional imaging, respectively. One patient exceeded whole-body dose of 2 Gy and demonstrated grade 3 hematologic toxicity, which resolved spontaneously within 12 mo after the therapy without the need for further treatment. Three patients (21%) demonstrated transient grade 1 renal toxicity.

Conclusion

124I-MIBG dosimetry-guided high-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or neuroblastoma resulted in durable responses with a low rate of manageable adverse events. Efficacy of 124I-MIBG-guided activity escalation should further be assessed in a prospective setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PheochromocytomaNeuroblastomaAdrenal Gland NeoplasmsChildHumansMaleAdolescentYoung AdultAdultMiddle AgedAged3-IodobenzylguanidinePositron Emission Tomography Computed TomographyProspective StudiesIodine Radioisotopes

Stichwörter der Autor:innen

MIBGdosimetrytheranosticstherapy

Substanzen

3-IodobenzylguanidineIodine-131Iodine RadioisotopesIodine-124

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany; ines.maric@uk-essen.de.
  • German Cancer Consortium (DKTK), partner site, Essen, Germany.
  • Department of Nuclear Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany; and.
  • Nuklearmedizin, MVZ CDT Strahleninstitut, Cologne, Germany.

Zitieren

APA

Maric, I., Weber, M., Prochnow, A., Schmitz, J., Unger, N., Schaarschmidt, B. M., Poeppel, T. D., Rischpler, C., Bockisch, A., Herrmann, K., Jentzen, W., & Fendler, W. P. (2023). Efficacy and Safety of 124 I-MIBG Dosimetry-Guided High-Activity 131 I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma. Journal of Nuclear Medicine, 64(6), 885-891. https://doi.org/10.2967/jnumed.122.264775

Vancouver

Maric I, Weber M, Prochnow A, Schmitz J, Unger N, Schaarschmidt BM, et al. Efficacy and Safety of 124 I-MIBG Dosimetry-Guided High-Activity 131 I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma. Journal of Nuclear Medicine. 2023;64(6):885-891. doi:10.2967/jnumed.122.264775

BibTeX
@article{Maric2023,
  author = {Maric, Ines and Weber, Manuel and Prochnow, Andre and Schmitz, Jochen and Unger, Nicole and Schaarschmidt, Benedikt M and Poeppel, Thorsten D and Rischpler, Christoph and Bockisch, Andreas and Herrmann, Ken and Jentzen, Walter and Fendler, Wolfgang P},
  title = {Efficacy and Safety of 124 I-MIBG Dosimetry-Guided High-Activity 131 I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {6},
  pages = {885--891},
  doi = {10.2967/jnumed.122.264775}
}
Kostenlos starten →